To advance Absci’s mission of creating better biologics for patients more quickly, Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows. With OCI, Absci ...

Fifth-generation AMD EPYC processors and RDMA cluster networking power OCI’s bare metal instances. They provide Absci with ...

Absci (ABSI) stock in focus as the company teams up with Oracle (ORCL) and AMD (AMD) to boost AI-powered drug discovery. Read ...

Advanced Micro Devices (AMD) recently formed a collaboration with Oracle Cloud Infrastructure and Absci to advance AI-driven drug discovery, leveraging its cutting-edge hardware like the Instinct ...

Advanced Micro Devices (AMD) experienced a notable increase of 35% over the last quarter, amidst its key collaboration with ...

Absci (ABSI) announced a collaboration with Oracle Cloud Infrastructure (ORCL) and AMD (AMD) to accelerate generative AI-driven drug discovery.

The alliance, originally announced in November 2023, combines Almirall’s dermatological capabilities with Absci’s Integrated ...

Discover how Absci leverages AI for breakthrough drug discovery, pipeline updates, and upcoming Phase II readouts.

Absci, a clinical-stage biotech company advancing therapeutics with generative AI, today - Read more from Inside HPC & AI News.

This breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic Creating antibodies in silico with generative AI represents a major ...

Absci says it is on track to advance its first antibody developed through its generative artificial intelligence (AI)-based platform to IND stage within the next 24 months, after the company disclosed ...

VANCOUVER, Wash., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation, a generative AI drug creation company, announced today that Zach Jonasson, Ph.D., has been appointed Chief Financial Officer (CFO ...